EarlySight is a Swiss startup company based in Geneva that has set out to revolutionize the care of eye diseases. Founded in 2019 as a spin-off of the prestigious Swiss Federal Institute of Technology in Lausanne (EPFL), EarlySight is at the forefront of the ophthalmic industry. The company has developed an imaging tool capable of observing the eye fundus at a microscopic level and measuring its biological structure.

By integrating artificial intelligence (AI) software, this tool has the potential to precisely detect and monitor disease biomarkers. EarlySight's mission is to reduce vision loss and enhance patients' quality of life by significantly improving the management of eye diseases. Their innovative technology, which stems from years of research at EPFL, enables improved diagnosis, monitoring, and treatment for millions of people.

Their products are designed, developed, and manufactured in Switzerland, known for its reliable and precise industry. With an ISO 13485 certification for their quality management system, EarlySight ensures the efficient processes and high-quality products required for medical professionals. They have already conducted successful clinical research projects with prototype technology, receiving positive feedback from end users and continuously refining their products.

Through a dedicated and skilled international team, including eminent medical advisors, EarlySight is committed to advancing ophthalmic care and making a significant impact in the field